⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17125261 | 0.79 | — | — | |
| SCHEMBL21865923 | 0.74 | — | — | |
| SCHEMBL1834515 | 0.74 | FFAR1 (0.32) | — | |
| SCHEMBL17125247 | 0.73 | FFAR1 (0.31) | — | |
| SCHEMBL493211 | 0.70 | FFAR4 (0.34) | — | |
| SCHEMBL15922574 | 0.70 | — | — | |
| SCHEMBL25246769 | 0.70 | SLC6A12 (0.38) | — | |
| SCHEMBL30466983 | 0.69 | — | — | |
| SCHEMBL31637478 | 0.68 | — | — | |
| SCHEMBL25244992 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681875-B1 | CYCLIC PEPTIDE ANTIBIOTICS | HOFFMANN LA ROCHE (CH) | 2026-01-14 | — | — | EP | disclosed |
| US-12358951-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| CN-111148739-B | Cyclic peptide antibiotics | 豪夫迈·罗氏有限公司 | 2025-06-03 | — | — | CN | disclosed |
| WO-2023069720-A1 | COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF | MONTE ROSA THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230025834-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| US-11279735-B2 | Cyclic peptide antibiotics | GENENTECH, INC. (US) | 2022-03-22 | — | — | US | disclosed |
| EP-3938377-A1 | CYCLIC PEPTIDE ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2022-01-19 | — | — | EP | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331968-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| WO-2020185999-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020185999-A1 | CYCLIC PEPTIDE ANTIBIOTICS | GENENTECH, INC. (US) | 2020-09-17 | — | — | WO | disclosed |
| CN-111148739-A | Cyclopeptide antibiotics | 豪夫迈·罗氏有限公司 | 2020-05-12 | — | — | CN | disclosed |
| WO-2019052545-A1 | CYCLIC PEPTIDE ANTIBIOTICS | F. HOFFMANN-LA ROCHE AG (CH) | 2019-03-21 | — | — | WO | disclosed |